Christian Medical College, Vellore, India.
Christian Medical College, Vellore, India.
Prog Mol Biol Transl Sci. 2018;157:151-174. doi: 10.1016/bs.pmbts.2018.01.005. Epub 2018 Apr 11.
There is increasing evidence that changes in epigenetic mechanisms of gene expression are involved in the pathogenesis of mood disorders. Such evidence stems from studies conducted on postmortem brain tissues and peripheral cells or tissues of patients with mood disorders. This article describes and discusses the epigenetic changes in the mood disorders (major depressive disorder and bipolar disorder) found to date. The article also describes and discusses preclinical drug trials of epigenetic drugs for treating mood disorders. In addition, nonrandomized and randomized controlled trials of nutritional drugs with effects on epigenetic mechanisms of gene expression in patients with major depressive disorder and bipolar disorder are discussed. Trials of epigenetic drugs and nutritional drugs with epigenetic effects are showing promising results for the treatment of mood disorders. Thus, epigenetic drugs and nutritional drugs with epigenetic effects could be useful in the treatment of patients with these disorders.
越来越多的证据表明，基因表达的表观遗传机制的改变与心境障碍的发病机制有关。这些证据源于对心境障碍（重性抑郁障碍和双相障碍）患者死后脑组织和外周细胞或组织进行的研究。本文描述并讨论了迄今为止在心境障碍（重性抑郁障碍和双相障碍）中发现的表观遗传变化。本文还描述并讨论了用于治疗心境障碍的表观遗传药物的临床前药物试验。此外，还讨论了重性抑郁障碍和双相障碍患者具有基因表达表观遗传机制作用的营养药物的非随机和随机对照试验。具有表观遗传作用的表观遗传药物和营养药物的试验显示出对心境障碍治疗有希望的结果。因此，具有表观遗传作用的表观遗传药物和营养药物可能对这些疾病患者的治疗有用。
